Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 201 to 250 of 761

TitleReference numberPublishedLast updated
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)TA785
Daratumumab monotherapy for treating relapsed and refractory multiple myelomaTA783
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerTA781
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)TA782
Nivolumab with ipilimumab for untreated advanced renal cell carcinomaTA780
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA779
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)TA774
Empagliflozin for treating chronic heart failure with reduced ejection fractionTA773
Dapagliflozin for treating chronic kidney diseaseTA775
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoeaTA776
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoeaTA777
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuriaTA778
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapiesTA772
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)TA771
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal)TA762
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitableTA763
Fremanezumab for preventing migraineTA764
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA765
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanomaTA766
Ponesimod for treating relapsing–remitting multiple sclerosisTA767
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA768
Palforzia for treating peanut allergy in children and young peopleTA769
Sodium zirconium cyclosilicate for treating hyperkalaemiaTA599
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA761
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA760
Cabotegravir with rilpivirine for treating HIV-1TA757
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsyTA758
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosisTA756
Belimumab for treating active autoantibody-positive systemic lupus erythematosusTA752
Cenobamate for treating focal onset seizures in epilepsyTA753
Mogamulizumab for previously treated mycosis fungoides and Sézary syndromeTA754
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)TA750
Dupilumab for treating severe asthma with type 2 inflammationTA751
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disordersTA748
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)TA749
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancerTA746
Nintedanib for treating progressive fibrosing interstitial lung diseasesTA747
Upadacitinib for treating moderate rheumatoid arthritisTA744
NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)TA745
Selpercatinib for treating advanced thyroid cancer with RET alterationsTA742
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerTA740
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA741
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitableTA739
Tofacitinib for treating juvenile idiopathic arthritisTA735
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapyTA736
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancerTA737
Berotralstat for preventing recurrent attacks of hereditary angioedemaTA738
Secukinumab for treating moderate to severe plaque psoriasis in children and young peopleTA734
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)TA732

Results per page

  1. 10
  2. 25
  3. 50
  4. All